Importance

Loading Importance Indicators...

Abstract

There is provided a compound of formula I: wherein: one or two of X.sup.5, X.sup.6 and X.sup.8 is N, and the others are CH; R.sup.7 is selected from halo, OR.sup.O1, SR.sup.S1, NR.sup.N1R.sup.N2, NR.sup.N7aC(.dbd.O)R.sup.C1, NR.sup.N7bSO.sub.2R.sup.S2a, an optionally substituted C.sub.5-20 heteroaryl group, or an optionally substituted C.sub.5-20 aryl group, where R.sup.O1 and R.sup.S1 are selected from H, an optionally substituted C.sub.5-20 aryl group, an optionally substituted C.sub.5-20 heteroaryl group, or an optionally substituted C.sub.1-7 alkyl group; R.sup.N1 and R.sup.N2 are independently selected from H, an optionally substituted C.sub.1-7 alkyl group, an optionally substituted C.sub.5-20 heteroaryl group, an optionally substituted C.sub.5-20 aryl group or R.sup.N1 and R.sup.N2 together with the nitrogen to which they are bound form a heterocyclic ring containing between 3 and 8 ring atoms; R.sup.C1 is selected from H, an optionally substituted C.sub.5-20 aryl group, an optionally substituted C.sub.5-20 heteroaryl group, an optionally substituted C.sub.1-7 alkyl group or NR.sup.N8R.sup.N9, where R.sup.N8 and R.sup.N9 are independently selected from H, an optionally substituted C.sub.1-7 alkyl group, an optionally substituted C.sub.5-20 heteroaryl group, an optionally substituted C.sub.5-20 aryl group or R.sup.N8 and R.sup.N9 together with the nitrogen to which they are bound form a heterocyclic ring containing between 3 and 8 ring atoms; R.sup.S2a is selected from H, an optionally substituted C.sub.5-20 aryl group, an optionally substituted C.sub.5-20 heteroaryl group, or an optionally substituted C.sub.1-7 alkyl group; R.sup.N7a and R.sup.N7b are selected from H and a C.sub.1-4 alkyl group; R.sup.N3 and R.sup.N4, together with the nitrogen to which they are bound, form a heterocyclic ring containing between 3 and 8 ring atoms; R.sup.2 is selected from H, halo, OR.sup.O2, SR.sup.S2b, NR.sup.N5R.sup.N6, an optionally substituted C.sub.5-20 heteroaryl group, and an optionally substituted C.sub.5-20 aryl group, wherein R.sup.O2 and R.sup.S2b are selected from H, an optionally substituted C.sub.5-20 aryl group, an optionally substituted C.sub.5-20 heteroaryl group, or an optionally substituted C.sub.1-7 alkyl group; R.sup.N5 and R.sup.N6 are independently selected from H, an optionally substituted C.sub.1-7 alkyl group, an optionally substituted C.sub.5-20 heteroaryl group, and an optionally substituted C.sub.5-20 aryl group, or R.sup.N5 and R.sup.N6 together with the nitrogen to which they are bound form a heterocyclic ring containing between 3 and 8 ring atoms, or a pharmaceutically acceptable salt thereof, with the proviso that when R.sup.2 is unsubstituted morpholino. R.sup.N3 and R.sup.N4 together with the nitrogen atom to which they are attached form an unsubstituted morpholino and R.sup.7 is unsubstituted phenyl, and X.sup.5 is CH, then X.sup.6 is not N and X.sup.8 is not CH, or X.sup.6 is not CH and X.sup.8 is not N, and when R.sup.2 is unsubstituted piperidinyl, R.sup.N3 and R.sup.N4 together with the nitrogen atom to which they are attached form an unsubstituted piperidinyl and R.sup.7 is unsubstituted phenyl, and X.sup.5 is CH, then X.sup.6 is not CH and X is not N. There are also provided processes for the manufacture of a compound of Formula 1, and the use of a compound of Formula 1 as a medicament and in the treatment of cancer.

Loading the Abstract Image...

First Claim